CTLA4 and non-small cell lung carcinoma: Laza-Briviesca et al., in a study of 27 stage IIIA NSCLC patients receiving neoadjuvant nivolumab plus carboplatin, found that patients who subsequently developed a pCR had greater expression on a per cell basis (MFI) of CD69 on intermediate monocytes, and lower frequencies of CD14++CD16+CTLA-4+ cells than patients who did not develop pCR [71].